GemVax

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • FX exposure 5% move → ±KRW 428M pre-tax impact on cash, receivables, payables in USD, JPY, SGD, CNY, EUR
• • Short-term financial liabilities due within 1 year KRW 64.1B, total contract liabilities KRW 74.5B at fiscal year-end

Management Discussion & Analysis

• • Revenue KRW 81.53B (+30.05% YoY), operating profit KRW 3.79B (from loss KRW -38.34B), net income break-even from loss KRW -87.09B
• • Environmental pollution control segment revenue KRW 7B, up 7.5% YoY driven by booming semiconductor industry demand

Business Overview

• • Chemical Air Filter and license contract revenues KRW 70.0B (85.9%) and KRW 11.5B (14.1%) respectively in FY2025
• • GV1001 license-out for progressive supranuclear palsy covering Korea, Japan, India, Indonesia started Dec 5, 2025, total KRW 220B contract

What are the latest GemVax DART filings in 2026?

GemVax (KRX code 082270) has filed an annual report on March 20, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did GemVax file its most recent annual report?

GemVax filed its most recent annual report on March 20, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is GemVax's KRX stock code?

GemVax's KRX stock code is 082270. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 082270 to look up all GemVax disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does GemVax file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for GemVax.

Where can I find GemVax financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from GemVax annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.